October 31, 2025

Single-Injection Omvoh Option Simplifies Ulcerative Colitis Care

The FDA approved Eli Lilly’s interleukin-23p19 antagonist Omvoh (mirikizumab-mrkz) as a once-monthly single-injection maintenance option for adults with moderately to severely active ulcerative colitis.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 29, 2025

Can SGLT-2 Inhibitors Shield Against Autoimmune Disease?

Researchers found sodium-glucose cotransporter-2 inhibitors lowered autoimmune rheumatic disease risk by 11% in adults with type 2 diabetes.

Conexiant

October 29, 2025

H-1B Visa Changes: Who Pays the Price?

New fee structure could hit hardest where physicians are needed most.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 10, 2025

Benign MS Associated With Weight, IM, and Fish Intake

Obesity, infection, and diet history evaluated in long-term benign multiple sclerosis.

Conexiant

August 27, 2025

FDA Approves LP.8.1 COVID-19 Vaccines

LP.8.1-targeted COVID-19 vaccines for adults 65 and older and higher-risk patients were approved by the US Food and Drug Administration.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant

April 30, 2024

Potential New Lyme Disease Therapy Advances to Human Safety Trials

The novel antibiotic therapy hygromycin A has advanced to human safety trials to determine its potential as a future treatment for Lyme disease.

Conexiant